Pletnev's drops possessing antiviral and immunomodulatory effects

FIELD: medicine.

SUBSTANCE: drops possessing antiviral and immunomodulatory effects characterised by the fact that they represent a 95% ethanol infusion of wild strawberry leaves and fruit specified in: red raspberry fruit, mountain ash fruit, bilberry fruit, blood-red hawthorn fruit, cinnamon rose fruit; 15-25 mg of the substance in 1 ml of the infusion.

EFFECT: drops possess pronounced antiviral and immunomodulatory effects.

15 tbl, 5 ex

 

The invention relates to the field of pharmacology, molecular biology and can be used in clinical medicine for the treatment of various diseases, pathogenesis of which is a violation of protein synthesis caused by various infectious agents, trauma and burns.

Recently, an increasing interest in drugs of natural origin, due to the peculiarities of their chemical composition, the components of which the structure is close to the metabolites of the human body and the relative safety of their application, which allows much broader than synthetic, to recommend them for prevention and treatment of various diseases.

An important feature of herbal medicines is that they contain significant amounts of biologically active substances with different severity healing properties that can significantly increase or diminish when they are combined. It is therapeutic effects of medicinal plants are fundamental in the preparation of formulations of complex herbal medicines (Herbal medicine with the basics of clinical pharmacology / ed. by V. G. Kukes. - M.: Medicine, 1999, p. 7).

Vladimir Pletnev has been proposed an original approach for the creation of new integrated herbal preparations for medicine on the basis of FA�makopane of plants with bioactive components of plant or of a different nature. Using this approach, established a comprehensive herbal drug seekarten (RF patent for the invention №2294209 from 27.02.2007) and Pletnev drops (RF patent for the invention №2466734 on 20.11.2012).

It is known that modern drugs used for antiviral and immunomodulatory therapy, often cause side effects, for example, when receiving: Amiksin, allergic reactions, dyspepsia, intermittent fever; acyclovir - abdominal pain, nausea, vomiting, diarrhea, transient increase in activity of liver enzymes, hyperbilirubinemia, leukopenia, erythropenia, headache, weakness, tremor, dizziness, fatigue, drowsiness, hallucinations, skin rash, allergic dermatitis, alopecia, fever, increased levels of urea and creatinine (Federal guidance on the use of medicines. Edition XII. - M.: "Echo", 2011, pp..47, 280, 282, 297, 435, 529, 530, 548, 585, 662, 680, 719, 826).

Known means on the basis of vegetable drugs with hepatoprotective, antimicrobial, antiviral, immunomodulatory and antioxidant activity.

Also known composition for the preparation of soft jelly drink containing, kg/100 kg: mangosteen extract of 0.2-0.4, Galanova gum 0,05-0,1, fruit and/or vegetable and/or vegetable puree 2,0-,0, fructose syrup 14,0-16,0, stevioside 0,02-0,03, citric acid 0,04-0,06 and water - the rest. The composition gives prigotavlivaemomu jelly non-alcoholic drink antioxidant, antibacterial, antiviral, anti-inflammatory, immunomodulatory and hepatoprotective properties and serves to prevent disease and improve the health of the person.

This tool is a soft drink and may not be used as a medicinal drug.

Closest to the proposed are Pletnev drops to restore metabolism and energy supply of tissues and organs constituting the infusion of one or two species of plant raw materials in 95% ethyl alcohol containing 15-25 mg of the substance in 1 ml of tincture, including the infusion of strawberry leaves and a second species of plant raw materials, such as nettle leaves (drops No. 1B), or plantain leaves (drops No. 2B), or leaves mother and stepmother (drops No. 4), or shoots of bilberry (drops No. 39), or grass, yarrow (drops No. 68). Drops contribute to the restoration of the structure and functions of biomembranes of cells, vascular endothelium, liver, nervous and immune system without side effects and addiction to drugs (RU 2466734 C1, pub. 20.11.2012).

However, the known drops have a very weak immune antiviral effects. Those that were used in the treatment of viral diseases such as HIV (drops No. 39) or chronic hepatitis C virus (drops No. 4 and No. 5), was used for rehabilitation, when some of the indicators of immune status was already in the normal range (in the treatment of chronic viral hepatitis C), and those that were outside the norm, resulting from the use of drops is not reached normal.

The object of the invention is the creation of new high-performance complex for herbal medicines, antiviral and immunomodulatory effects that do not cause any side effects, getting used to it and used both independently and in combination with standard therapy.

The technical result of the invention is to provide an effective antiviral and immunomodulatory therapy without side effects and addiction to the drugs.

For the task offered drops, antiviral and immunomodulatory effects, which are called "Pletnev Drops". They represent the tincture obtained by extraction from plant material with an organic solvent.

Drops Pletnev represent the infusion of two types of plant raw materials containing in the aggregate selenium, zinc, vitamin e, chlorophyll, 95% ethyl alcohol (f� 42-3072-00) when the content of 15-25 mg of the substance in 1 ml of tincture.

The options are formulations Pletnev drops.

1. Drops Pletnev No. 204 represent the infusion of strawberry leaves (FS 42-134-72) and fruits of red raspberry (GOST 3525-75) containing selenium, chlorophyll (strawberry leaves), zinc and vitamin R (raspberry fruit).

2. Drops Pletnev No. 207 represent the infusion of strawberry leaves (FS 42-134-72) and ashberries (GF XI, issue 2, article 25) containing selenium, chlorophyll (strawberry leaves), zinc, vitamins P, C (Rowan berries).

3. Drops Pletnev No. 212 represent the infusion of strawberry leaves (FS 42-134-72) and bilberry fruit (GF XI, issue 2, article 25) containing selenium, chlorophyll (strawberry leaves), zinc, vitamins P, C, quercitrin (blueberry fruits).

4. Drops Pletnev No. 236 represent the infusion of strawberry leaves (FS 42-134-72) and fruits of hawthorn blood-red (GF XI, issue 2, article 25) containing selenium, chlorophyll (strawberry leaves), zinc, vitamins P, C, E (hawthorn).

5. Drops Pletnev No. 245 represent the infusion of strawberry leaves (FS 42-134-72) and hips may (GF XI, issue 2, article 25) containing selenium, chlorophyll (strawberry leaves), zinc, vitamins P, C, PP (hips).

Drops Pletnev made as follows.

As starting materials chosen plant material two species containing both�spine selenium, zinc, vitamin e and chlorophyll, the leaves of the wild strawberry and raspberry fruits, or Rowan, or bilberry, or of hawthorn blood-red, or majalis. The crop material is pre-dried and milled. To select the process mode, examine the kinetics of extraction of plant material and determine the time setting of the dynamic equilibrium in the system solid-liquid active substances. 100 g of the dried and ground green mass is placed in a glass container and pour 95% ethyl alcohol in a ratio of 1:10. Extract obtained in the extraction of raw materials, settled in the sump within regulated at the ND time. The obtained extract was filtered through an ultrafiltration membrane (pore size 0.2 µm). Made the infusion dispenser Packed in vials or ampoules different capacity, sealed and packaged.

Experimental study of the pharmacological properties and toxicity Pletnev drops№204, 207, 212, 236, 245 showed:

1. Drops Pletnev№204, 207, 212, 236, 245 possess immunomodulatory and antiviral properties.

In the range of tested doses Pletnev drops№204, 207, 212, 236, 245 stimulate humoral and cellular immunity, increase phagocytic activity, Strait�ferariu of limfotsitov and production of TNF-α by mononuclear cells.

With the introduction of preventive 24 hours before infection of mice with a lethal dose of Staphylococcus pyogenes Pletnev drops№204, 207, 212, 236, 245 increase their survival rate up to 75% with 84% of the deaths in the control.

In experiments in vitro Pletnev drops№204, 207, 212, 236, 245 in the tested dilutions completely inhibit the growth of Staphylococcus aureus and Escherichia coli, completely inhibited the growth of Pseudomonas aeruginosa and Acinetobacter calcoaceticus.

Drops Pletnev№204, 207, 212, 236, 245 in different schemes of administration (before, during and after infection of cell cultures) exhibit a pronounced antiviral activity against several pathogenic human and animal viruses. Drops Pletnev№204, 207, 212, 236, 245 inhibited in cell culture replication of avian influenza viruses A/H5 in the tested doses, while reducing their infectious titer of 2.0 to 3.0 by lg.

Drugs effective in experiments on chicken embryos, replication of the virus and exhibit virucidal action. In mice, they have a protective effect in the tested doses in viral pneumonia, increasing the survival of animals up to 60-100% at 100% death in the control.

In experiments in vitro Pletnev drops№204, 207, 212, 236, 245 in the tested dilutions have antiviral and virucidal effect on HSV-1. Drugs have a virucidal effect on extracellular virus not only herpes simplex-1, but also on the strains of virus sensitivity�tion and resistant to acyclovir.

Introduced to the cell culture for 24 hours before infection with hepatitis C virus Pletnev drops№204, 207, 212, 236, 245 in the tested dilutions protect 100% of infected cells from cytopathogenic the virus in 100% cell death in control. The antiviral effect of drugs is maintained during their introduction during and 24 hours after infection of cells with this virus.

In experiments in vitro Pletnev drops№204, 207, 212, 236, 245 in the tested dilutions have antiviral and virucidal effect on the human immunodeficiency virus-1.

2. Drops Pletnev№204, 207, 212, 236, 245 are low-toxic drugs in a single laboratory animals and are well tolerated with long-term administration to Wistar rats (3 months) and dogs (1 month) not cause any injury to major organs and systems of experimental animals and do not show local irritative effect.

Drops Pletnev№204, 207, 212, 236, 245 't have the mutagenicity and DNA-damaging effect. In the tested doses and the regimen of administration of the drugs do not show allergenic and immunotoxic properties.

When prescribing to pregnant rats Pletnev drops№204, 207, 212, 236, 245 show embryotoxicity, so pregnancy is a contraindication to the administration of drugs.

The use of the proposed antiviral drops for them and�unimodularly therapy is as follows.

Received Pletnev drops represent a solution of the active substance in 95% ethanol, 1 ml of which contains 15-25 mg of drug substance. Drops Pletnev No. 204 is administered orally.

When administered orally, the dose is calculated as follows:

in 20 drops of a solution contains 15 to 25 mg of drug substance;

10 drops (1/2) of the solution contains 7.5 to 12.5 mg of drug substance;

5 drops (1/4) of solution contains 3,75-6,25 mg drug substance;

3 drops (1/7) of solution contains 2.25 to 3.75 mg of drug substance.

The duration of treatment is 2-3 months, depending on the condition of the patient. Repeat courses of treatment recommended by your physician. During the treatment, monitor the patient's condition according to the analysis of blood, urine, biochemical blood tests, immunological, virological and research tools.

When applying Pletnev drops there is a relative normalization of blood, urine, biochemical blood tests, immunological, virological and instrumental studies, showing clinical improvement of the patients ' health.

Examples of antiviral and immunomodulatory therapy using the suggested drops.

Example 1.

�Olney M., 19. Clinical diagnosis: Chronic viral hepatitis C, the phase of active virus replication.

Considers himself ill since March 2011, when there was a dull pain, feeling of heaviness in the right hypochondrium and jaundice, urine color was dark. In the infectious diseases hospital in the survey were found anti-HCV and HCV RNA. Began in 2011 combined antiviral therapy (Pegasys+ribavirin) for 6 months with improvement.

Patient M. came to us 26.08.2013 year. Complaints of dull pain and a feeling of heaviness in the right hypochondrium, nausea, fatigue in the evening. Consciousness is clear. The skin yellow. Sclera ikterichnost. Visible mucous yellow, moist, clean. Tongue coated with white bloom. The body temperature of 36.5°C. vesicular Breathing. RR: 16/min, heart sounds rhythmic. BP: 110/70 mm Hg.PT. The pulse: 57/min. Marked tenderness in the right upper quadrant on palpation. In other areas of the abdomen is soft, painless. The edge of the liver was dense texture, spicy, comes out from under the costal margin 3 cm, smooth surface of the liver. Urine dark. The chair is light, mushy - 1 per day. There is no swelling.

Patients were asked to rate (90 days) treatment Pletnev drops No. 204.

With the oral consent of the patient therapy Pletnev drops No. 204 according to the following scheme: inside 5 drops of the drug dissolving in 50 ml boil�ow of water at room temperature, 1 times daily in the morning before eating for 20 minutes.

- Laboratory tests:

After the first course of treatment on 22.11.2013 year: notes the improvement of health. No complaints. The body temperature was 36.6°C. vesicular Breathing. RR: 18/min, heart sounds rhythmic. BP: 110/70 mm Hg.PT. Heart rate: 60/min. the Abdomen is soft, painless. Liver, spleen not palpable. Dysuric phenomena no. There is no swelling.

Conclusion: the 90-day course of treatment Pletnev drops No. 204 with a positive effect. Recommended therapy in the same volume. Is the follow-up.

Example 2.

Patient A., age 36. Clinical diagnosis: HIV infection stage 4A (herpes zoster history, onychomycosis), phase progression. Chronic viral hepatitis C.

The anamnesis of disease: sick with 25.05.2011, when the survey was identified RNA HIV-1, anti-HCV and HCV RNA. The sexual route of infection. The treatment was carried out.

Patient a came to us 08.02.2012 year. Complaints of headache, fever up to 38.5°C, cough, nasal congestion, weakness, fatigue, enlarged lymph nodes, increased excitability. The body temperature of 38.5°C. Breathing hard. RR: 20/min, heart sounds rhythmic, muted. BP: 110/70 mm Hg.PT. The pulse: 75/min. the Abdomen is soft, painless. The liver, salute�ka is not palpable. Dysuric phenomena no. There is no swelling.

The patient is recommended to attend the course (90 days) treatment Pletnev drops No. 207.

With verbal consent, the patient underwent therapy Pletnev drops No. 207 according to the following scheme: inside 15 drops of the drug dissolving in 50 ml of boiled water at room temperature, 2 times a day, morning and evening before meals within 20 minutes.

- Laboratory tests:

After the first course of treatment on 05.05.2012 year: notes the improvement of health. No complaints. Became active. Weakness no. The body temperature was 36.6°C. vesicular Breathing. RR: 18/min, heart sounds rhythmic. BP: 120/80 mm Hg.PT. Heart rate: 60/min. the Abdomen is soft, painless. Liver, spleen not palpable. Dysuric phenomena no. There is no swelling.

Conclusion: the 90-day course of treatment Pletnev drops No. 207 with a positive effect. Recommended therapy in the same volume. With 05.05.2012 years the patient treatment Pletnev drops No. 207 fails due to relocation to another region of Russia.

Example 3.

Patient A., age 36. Clinical diagnosis: Cirrhosis in the outcome of chronic viral hepatitis C. Edematous-ascitic syndrome. Varicose veins of the esophagus I art Thrombocytopenia. The jaundice.

Considers herself a patient of 2008, when the survey revealed �STI-HCV and HCV RNA. In 2008 the combined antiviral therapy (Pegasys+ribavirin) for 6 months with improvement.

Patient a came to us 14/02/2013. Complaints of weakness, sweating, loss of appetite, dark urine, yellowing of the skin and sclera. When contacting the state of moderate severity. Skin, sclera jaundice. Isolated hemorrhages on the skin of the trunk, face, extremities. Body temperature is 36.8°C. vesicular Breathing. RR: 20/min, heart sounds rhythmic. HELL: 135/80 mm Hg.PT. Heart rate: 70/min. the Abdomen is soft, painless. Liver at the edge of the costal arch, dense, palpable spleen in the left hypochondrium, dense. Dysuric phenomena no. The formation of ascites by ultrasound.

Instrumental studies:

Ultrasound from 04.02.2013: the liver is typically located in the right upper quadrant. Subphrenic space without additional inclusions. The mobility of the liver during respiration is not limited. The capsule is visualized in the plots are not thickened, not deformed. The contour of the body clear, smooth, can be traced throughout. The edge is rounded, not prominent. The typical form without defects. The increased size of the liver: right lobe: anterior-posterior - 168 mm (up to 130 mm); cranio-caudal - 91 mm (up to 125 mm); left lobe: anterior-posterior - 87 mm (70 mm); caudate lobe: anterior-posterior - 37 mm (35 mm).

The liver parenchyma with Yach�East, large, coarse-grained the echostructure. The echogenicity of the parenchyma moderately increased unevenly all over. Vascular pattern of the portal system depleted. Vessels are not sufficiently traced in the main divisions, poorly visible on the periphery. Periportal structures are not sealed.

The spleen is usually enlarged: 197-76 mm (up to 130-50 mm). The lumen of the vessels of the portal system expanded. Portal vein (transmasculine) 12.8 mm, splenic vein (in the gate) of 14.4 mm. Speed of flow is reduced to 14.5 and 13 cm/sec. Free fluid sparse clusters in the space of Marrison, meritline intervals. Conclusion: hepatosplenomegaly. Diffuse changes in the structure of the liver. Portal hypertension with hemodynamic disturbances. The formation of ascites.

EGDS from 06.02.2013. Conclusion: varicose veins of the esophagus I art, the risk of bleeding is low. Hemorrhagic antral gastritis. Surface mixed gastritis of the gastric body. Surface bulbit. Failure of the cardia.

Patient recommended course (90 days) treatment Pletnev drops No. 245.

With the oral consent of the patient therapy Pletnev drops No. 245 according to the following scheme: inside 5 drops of the drug dissolving in 50 ml of boiled water at room temperature, 2 times a day, morning and evening before meals within 20 minutes.

Laboratory IP�research:

15.08.2013 year. There are complaints on sweating. Noted improvement in health. The body temperature was 36.6°C. vesicular Breathing. RR: 18/min, heart sounds rhythmic. BP: 120/80 mm Hg.PT. The pulse: 75/min. the Abdomen is soft, painless. Liver at the edge of the costal arch, dense, palpable spleen in the left hypochondrium, dense. Dysuric phenomena no. There is no swelling.

Conclusion: after the 2 courses of treatment Pletnev drops No. 245 on 15.08.2013 year: notes the improvement of health. Recommended therapy in the same volume. Is the follow-up.

Example 4.

Patient V., 64. Clinical diagnosis: HIV infection stage 3A (herpes simplex virus in history), phase transition.

The anamnesis of disease: ill since 1998, when the examination in the blood was detected RNA HIV-1. Refused treatment.

Patient V. asked us 16.02.2013. Complaints of sore throat, frequent fever up to 38°C, night sweats, weakness, fatigue, irritability, loss of body weight up to 10%, skin rashes, herpetic eruptions on the skin, enlarged lymph nodes. The body temperature of 37.3°C. Breathing hard. RR: 22/min, heart sounds rhythmic, muted. BP: 135/85 mm Hg.PT. The pulse: 92/min, the Abdomen tense, painless. Periodic diarrhea. Symptom of Pasternatskogo negative. M�cheaponline painless, free. There is no swelling.

Patients were asked to rate (90 days) treatment Pletnev drops No. 212.

With the oral consent of the patient therapy Pletnev drops No. 212 according to the following scheme: inside 20 drops of the drug dissolving in 50 ml of boiled water at room temperature, 1 time a day in the morning before eating for 20 minutes.

- Laboratory tests:

18.05.2013. No complaints. Noted improvement in health. Active. No complaints. The body temperature was 36.6°C. vesicular Breathing. RR: 18/min, heart sounds rhythmic. BP: 120/80 mm Hg.PT. Heart rate: 60/min. the Abdomen is soft, painless. Liver, spleen not palpable. Dysuric phenomena no. There is no swelling. Continues to accept Pletnev drops No. 212.

15.08.2013 year. No complaints. Feeling good. The body temperature of 36.7°C. vesicular Breathing. RR: 18/min, heart sounds rhythmic. BP: 120/80 mm Hg.PT. Heart rate: 65/min. the Abdomen is soft, painless. Liver, spleen not palpable. Dysuric phenomena no. There is no swelling.

Conclusion: the conducted 2nd year (every 90 days) treatment Pletnev drops No. 212 with a positive effect. Recommended therapy in the same volume. Is the follow-up.

Example 5.

E. the patient, 25 years. Clinical diagnosis: HIV infection stage 2A (URTI, tonsillitis), initial phase (acute).

The anamnesis of disease: sick with 22.07.11 when PR� examination discovered RNA HIV-1. The treatment was carried out.

E. the patient came to us 08.08.2011 year. Complaints of headache, sore throat, fever up to 38°C, cough, nasal congestion, weakness, fatigue, enlarged lymph nodes, increased excitability. Body temperature 38°C. Breathing hard. RR: 20/min, heart sounds rhythmic, muted. BP: 110/70 mm Hg.PT. Pulse: 80/min. the Abdomen is soft, painless. Liver, spleen not palpable. Dysuric phenomena no. There is no swelling.

The patient is recommended to attend the course (90 days) treatment Pletnev drops No. 236.

With verbal consent, the patient underwent therapy Pletnev drops No. 236 according to the following scheme: inside 15 drops of the drug dissolving in 50 ml of boiled water at room temperature, 1 time a day in the morning before eating for 20 minutes.

- Laboratory tests:

27.11.2011 year: good health. No complaints. Became active. The body temperature of 36.7°C. vesicular Breathing. RR: 16/min, heart sounds rhythmic. BP: 110/70 mm Hg.PT. Heart rate: 60/min. the Abdomen is soft, painless. Liver, spleen not palpable. Dysuric phenomena no. There is no swelling. Therapy continues in the same volume.

10.10.2013: feeling good. No complaints. The body temperature of 36.5°C. vesicular Breathing. RR: 18/min, heart sounds rhythmic. BP: 115/75 mm Hg.PT. Heart rate: 65/min. �ivot soft, painless. Liver, spleen not palpable. Dysuric phenomena no. There is no swelling.

Conclusion: after the 8 courses of treatment Pletnev drops No. 236 on 10.10.2013: feeling good. HIV-1 RNA from 31.05.2012 and from 05.10.2013 - not detected. No complaints. Recommended: prophylactic course (90 days) of receiving Pletnev drops No. 236 1 once a year; monitoring over time; a blood test, biochemical blood tests, immunological - 6 months.

Therapy patients with HIV infection, viral hepatitis, demyelinating diseases of the nervous system, blood diseases, cancer is an extremely difficult task. We have to admit that at the present time, the treatment according to the accepted standards often prevents dramatic for these diseases.

In the clinical examples№1, 2, 3, 4, 5 summarizes the experience of applying drugs Pletnev drops№204, 207, 212, 236, 245 in the treatment of various diseases with their unifying pathogenetic mechanisms: disruption of the structure and function of biomembrane cells, vascular endothelium, as well as immunopathological changes caused by the violation of a single immune-biochemical mechanism of regulation of homeostasis.

The analysis of the dynamics of clinical and laboratory parameters in patients taking Pletnev drops No. 204, 27, 212, 236, 245 as monotherapy, show normalization of indicators of cellular immunity (CD3, CD4, CD8, CD16, CD56), peripheral blood (leukocytes, erythrocytes, platelets, neutrophils, lymphocytes), biochemical parameters (aminotransferases, alkaline phosphatase, glutamyltranspeptidase, bilirubin, total protein). In General, this may indicate that accurate correction of the immune system, and restoring the consistency of the relationship of hematologic, endocrine, neurological, and biochemical status.

Drops, antiviral and immunomodulatory effects, characterized by the fact that they represent the infusion of 95% ethyl alcohol strawberry leaves and fruits, selected from the series: the fruit of the red raspberry, the fruit of the Rowan tree, the fruit of bilberry, hawthorn blood-red, rose hips may, when the content of 15-25 mg of the substance in 1 ml of tincture.



 

Same patents:

FIELD: medicine.

SUBSTANCE: melanin having water-solubility of at least 80% and an paramagnetic centre concentration of at least 8·1017 spin/g is administered orally into the animals having been exposed to the radiation in a dose high enough to cause a spinal radiation injury; melanin is administered after dissolved in distilled water in the effective concentration. Melanin water is used as drinking water for the mice having been exposed to single and fractionated acute radiation, which is able to cause acute radiation disease. Melanin water is taken from the 1st to 30th day following the single radiation, or from the 1st day of the fractionated radiation to the 30th day on completion of the radiation.

EFFECT: higher survival rate, faster recovered haemopoiesis, body weight and orientation and motion activity.

7 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention provides a composition having antioxidant properties in the form of a tablet, comprising an active agent based on nicotinamide adenine dinucleotide in reduced form (NADH) and inert filling agents, characterised by that the active ingredient is a complex which is a mixture of 10 wt % NADH with 63 wt % vegetable fats, 17 wt % beeswax and 10 wt % chlorophyll, and the inert filling agents are in the form of microcrystalline cellulose, Macrogol 6000, intense sweetener and a food flavourant.

EFFECT: invention provides a new tablet form of NADH.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to a pharmaceutical composition with anti-ischemic and antioxidant activity in the form of tablets or capsules, and a method for preparing it. The composition contains 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid in an amount of 40 to 80 wt %, an amino-containing compound and pharmaceutically acceptable excipients. The amino-containing compound is specified in a group of trometamol, methyl glucamine and L-lysine; 1 mole of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid is accounted for 0.05 to 0.25 mole of the above amino-containing compound. The composition also contains lactose, microcrystalline cellulose, calcium stearate and other pharmaceutically acceptable excipients. According to the method for preparing the composition, taking 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid and amino-containing compound in molar ratio 1:0.05 to 1:0.25, pre-mixing, moisturising with a aqueous or alcohol solution of a binding agent, adding pharmaceutically acceptable excipients in such an amount to provide the content of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid from 40 to 80 wt %, granulating the mixture, drying and producing tablets or capsules according to the known technique.

EFFECT: implementing the above application.

6 cl, 7 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: claimed is the application of 5(6)-nitro-1-(1,1-dioxothietanyl-3)-2-chlorobenzimidazole of formula (I) , earlier known as the means with broncholytic and spasmolytic activity, as the means, inhibiting peroxide oxidation of lipids.

EFFECT: realisation of the claimed purpose.

1 dwg

FIELD: chemistry.

SUBSTANCE: claimed is the application of 5(6)-nitro-2-chloro-benzimidazole of formula (I) as the preparation, inhibiting peroxide oxidation of lipids.

EFFECT: achievement of the claimed purpose, activity of the said formula compound is higher than of the comparison medication dibazole.

1 dwg

FIELD: medicine.

SUBSTANCE: method for preparing an agent possessing anti-inflammatory, diuretic and antioxidant activity, involving milling Spiraea salicifolia shoots representing a mixture of leaves, blossom and shoots, extracting them three times by gradual maceration, mixing in infusing, filtering, condensing, separating, drying in the certain environment.

EFFECT: agent shoes the pronounced anti-inflammatory, diuretic and antioxidant activity.

2 dwg, 12 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and can be used as a hepatotrophic, lipotropic agent in gastroenterology, as well as for treating cardiac and cerebral atherosclerosis, in neurology in the lower extremity artery diseases (endarteritis). The agent contains tabletted powders of diisopropylammonium dichloroacetate, microcrystalline cellulose, lactose and excipients presented by Aerosil, Primogel and calcium stearyl fumarate.

EFFECT: agent possesses no toxicity, has the high adsorption properties, the apparent anti-inflammatory action, and provides metabolism and the liver regeneration.

3 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to heterocyclic compound - 6-methyl-5-morpholynomethyl-1-(thiethan-3-yl)pyrimidine-2,4(1H,3H)-dione of formula 6-methyl-5-morpholynomethyl-1-(thiethan-3-yl)pyrimidine-2,4(1H,3H)-dione of formula: .

EFFECT: novel compound, possessing antioxidant activity, is obtained.

2 cl, 6 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition for treating gastroduodenal ulcer in the form of tablets, capsules or gel, containing therapeutic agents and a consistency base applicable for each dosage, wherein the therapeutic agents are as follows: recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; antiseptics; amino acids specified in a group: arginine, histidine, lysine, cysteine, methionine, glutamic acid; and antioxidants specified in a group: beta-carotene, vitamin C, vitamin E.

EFFECT: invention has the integrated body effect promoting faster healing of the mucosal defect accompanying the aggravated gastroduodenal ulcer and preventing recurrences, including by the eradication effect.

6 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition in the form of tablets for oromucosal administration in treating infectious-inflammatory oropharyngeal diseases. The composition contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; amino acid specified in a group: arginine, histidine, glycine, glutathione, lysine, methionine, cysteine; an antiseptic, a preserving agent, flavours specified in a group: tea tree oil, eucalyptus leaf oil, mint leaf oil and a consistence base.

EFFECT: invention makes the composition applicable in fragile and frequently ill patients for reducing a disease recurrence.

7 cl, 1 ex

FIELD: biotechnology.

SUBSTANCE: increase in biocidal and immunobiological action due to the use of distilled water ionised with silver ions and adding into the composition of succinic, ascorbic, citric acid and aethonium.

EFFECT: increase in biocidal immunobiological properties of the antiseptic-stimulant of Dorogov ASD-2F.

6 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method includes carrying out complex treatment at the background of diet therapy. Intake of antihelmintic of vegetable origin and immunomodulator is carried out daily with washing down each of them with 200 ml of radon water. Intestinal lavage is performed every second day. On days of performing intestinal lavage, patient takes bath with radon water in the morning before lavage, with performing underwater hydrodynamic massage (UHM) on other days. On days, when intestinal lavage is not performed, sessions of sound therapy are carried out after UHM.

EFFECT: method provides correction of biological age of organism as prevention of premature ageing.

3 cl, 4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: before Mantoux test with 2 TE PDD-L, Ergoferon preparation is used in the infants infected with tuberculosis mycobacteria with the suspected early period of primary tuberculosis infection and active tuberculosis infection, in a dose of 1 tablet 20-30 minutes before or after a meal, once a day for 45 days.

EFFECT: invention provides the complex preparation of frequently and chronically ill children with an allergic pathology, for Mantoux test with 2 TE PDD-L.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: before Mantoux test with 2 TE PPD-L, general advice for phthisiologist-controlled preparation of the infants are given. That is added with prescribing the immunomodulatory preparation Anaferon for children aged 1 year and older 1 tablet 20-30 minutes before and after meals once a day for 30 days.

EFFECT: invention provides the complex preparation of frequently and chronically ill children for Mantoux test with 2 TE PDD-L.

3 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology, specifically to immunostimulating compounds and may be used in medicine. An immunostimulating peptide of an amino acid sequence XLYDKGYTSKEQKDCVGI, where N-terminal X is N-acetylalanine, and may be covalently linked to fatty acids, selected from C2-C25, to form PDAG (peptidyl-2,3-diacylglycerides). The resulted compound may be included in pharmaceutical formulations for stimulating an immune response.

EFFECT: invention provides efficient stimulation of an immune response in subjects and may enhance the immunogenicity of the antigenic peptide when administered with PDAG.

29 cl, 10 dwg, 9 ex

FIELD: medicine.

SUBSTANCE: first stage involves a cervical uterine repair by staged dissection on the 5-7th menstruation day in a combination with laser destruction of exophytic condylomas. Laser light power is 6-9 Wt, spot diameter is 1.5 mm, and exophytic condylomas penetration is 1-1.5mm. The second stage involves the immunomodulatory therapy.

EFFECT: method enables increasing the clinical effectiveness by recovering the immunological homeostasis of the uterine cervix by potentiating two effects: recovering archtechtonics of the cervical canal and immunomodulatory therapy.

4 tbl, 2 ex

Fingolimod salts // 2543621

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new 2-amino-2-[2-(4-C2-20alkylphenyl)ethyl]propan-1,3-diol salts specified in tartrate, lactate benzoate, succinate, malonate, acetate and propionate in the crystalline form. Each of the above salts is characterised by powder X-ray pattern data. Compounds in the therapeutically effective amount can be used in treating autoimmune diseases.

EFFECT: crystalline salts of the present invention possess higher stability, better solubility, more convenient to store and handle.

11 cl, 7 dwg, 1 tbl, 10 ex

FIELD: pharmacology.

SUBSTANCE: invention mainly relates to a food composition, including punicalagins.

EFFECT: improved action in respect to health improvement.

8 cl, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of organic chemistry, namely to heterocyclic compound of general formula (I) or to its pharmaceutically acceptable salt, acid salt or stereoisomer, where Y: NRa and N+R1R2X-; Z: bond, -(CH2)p, -CHOH, -CH=CH-, -C≡C-, -CONH- and -CO-; Rb: C1-C8 alkyl, C2-C8 alkenyl, C6-C10 aryl, -NR5R6,: , and ; with each alkyl, alkenyl and aryl, representing Rb, possibly, contains 1-3 substituents, selected from C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C1-C4 alkoxy, C6-C10 aryl, 5-, 6- and 7-membered heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, halogen, -OH, -NH2, -CN and -NO2; Rc: halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkinyl, C3-C10 cycloalkyl, C3-C8 cycloalkenyl, C1-C4 alkoxy, C6-C10 aryl, 5-, 6-, 7- and 8-membered monocyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, 9- and 10-membered bicyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur; with C1-C6 alkyl, C2-C6 alkenyl C2-C6 alkinyl, C3-C10 cycloalkyl, C3-C8 cycloalkenyl, C6-C10aryl, 5-, 6-, 7-, 8-membered monocyclic heterocyclyl and 9- and 10-membered bicyclic heterocyclyl, representing Rc, possibly contain 1-5 substituents, selected from the group, consisting of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C6 cycloalkyl, C4-C8 cycloalkenyla, halogen, -OH, -NH2, C6-C10 (A)(A')(A")(A'")aryl, (A)(A')(A")(A'")heterocyclyl, containing 1-3 heteroatom, selected from nitrogen, oxygen and sulphur, NR14R15, (CH2)pNR14R15, -CN, -NO2, oxo, -COOR14, SOR14, SO2R14, SO2NR14R15, NR15SO2R16, COR14, CONR14R15 and NR15COR16; with each (A), (A'), (A") and (A'")independently absent or representing C1-C4 alkyl, and each heterocyclyl (A)(A')(A")(A'")heterocyclyl is independently selected from the group, consisting of 5-, 6-, 7- and 8-membered monocyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, and 9- and 10-membered bicyclico heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur; the remaining radicals have values given in i.1;and on condition that, if Rc represents heterocyclyl, said heterocyclyl is bound directly through carbon atom of heterocyclyl ring. Invention also relates to particular compounds and to pharmaceutical composition based on formula (I) compound.

EFFECT: obtained are novel imidazopyrazine and imidazodiazepine derivatives, useful for prevention or treatment of disease or condition, severity of which is reduced by receptors to cannabinoids.

21 cl, 5 dwg, 4 tbl, 71 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to isoxazoline FAAH inhibitors of formula (I) or their pharmaceutically acceptable forms, wherein each of G, Ra, Rb, Rc and Rd has a value described in the present application, to pharmaceutical compositions, and methods of treating a FAAH-mediated condition.

EFFECT: developing the method of treating the FAAH-mediated condition.

32 cl, 22 tbl, 351 ex

FIELD: chemistry.

SUBSTANCE: method includes treating crushed Echinacea purpurea (L.) Moench roots and rhizome with steam, extraction with ethyl alcohol, then steeping, stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench roots and rhizome, after draining a portion of the extract, adding ethyl alcohol to the treated material, draining the whole extract; extracting crushed Echinacea purpurea (L.) Moench herbs with ethyl alcohol, steeping, then stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench herbs, after draining a portion of the extract, adding ethyl alcohol to the treated herbs, draining the whole extract; all obtained extracts are mixed, cooled and filtered under certain conditions. An Echinacea purpurea (L.) Moench tincture. Use of the method to obtain an Echinacea purpurea (L.) Moench tincture.

EFFECT: method preserves the biological activity of components of the tincture and medicinal properties.

3 cl

Up!